Kevin Bordelon
Internal Medicine · Marksville, LANPI 1972506491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 27.3% of the total.
Across 88 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$417
- Lilly USA, LLC$346
- AstraZeneca$189
- Boehringer Ingelheim$85
- Exact Sciences$69
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$53
- plus $367 from 12 others
What the payments were for
- Food & beverage$1,526100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $417 |
| Lilly USA, LLC | 21 | $346 |
| AstraZeneca | 10 | $189 |
| Boehringer Ingelheim | 5 | $85 |
| Exact Sciences | 3 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Amgen | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Acadia Pharmaceuticals Inc | 2 | $48 |
| AbbVie | 3 | $43 |
| GSK | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$1,526 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 221 | $240,966 |
| TrulicityDulaglutide | 67 | $71,098 |
| EliquisApixaban | 57 | $63,764 |
| JardianceEmpagliflozin | 51 | $56,496 |
| MounjaroTirzepatide | 44 | $55,347 |
| FarxigaDapagliflozin Propanediol | 25 | $27,609 |
| XareltoRivaroxaban | 16 | $25,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $24,789 |
| JanuviaSitagliptin Phosphate | 15 | $19,916 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $17,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $17,514 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,897 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $11,225 |
| LinzessLinaclotide | 13 | $8,934 |
| Dexlansoprazole DrDexlansoprazole | 31 | $8,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $417 | $240,966221 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $346 | $126,445111 claims |
| Boehringer IngelheimJardiance | $85 | $56,49651 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $33 | $42,30351 claims |
| AstraZenecaFarxiga | $189 | $27,60925 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $50 | $13,89716 claims |
| AbbVieLinzess, Synthroid | $43 | $11,24241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Marksville
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
- Bryan LebeanLafayette$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.